Answers are grounded in this paper and cite their sources.
Although Kaposi described “idiopathic multiple pigmented sarcoma of the skin” in 1872 (1), the disease was a medical curiosity in Europe and the United States until the acquired immune deficiency syndrome (AIDS*) epidemic was recognized in 1981. The annual incidence was 0.021-0.061 per 100,000 people (2). Kaposi's sarcoma (KS) comprised only 0.02-0.07% of all cancers in the United States (3, 4). KS is a tumor, often of multicentric origin, composed of differing proportions of endothelium-lined vascular spaces and spindle-shaped cells (3). In addition, extravasated red blood cells and clusters of inflammatory cells including lymphocytes and plasma cells may be present. The cell of origin is controversial, and KS has been variously classified as a fibrosarcoma, an endotheliosarcoma, and a lymphoma. However, most investigators agree that it is of endothelial origin (5), and lymphatic endothelial cells appear to be the most likely source (6). This fits with clinical observations that lesions often have a striking cutaneous lymphatic distribution, and lymphedema is frequently present (5). KS occurs in several clinical settings, described below Clinical Settings of Kaposi's Sarcoma Classical KS. Classical KS affects elderly men, mostly Jews of Central and Eastern European origin, and persons of Southern European ancestry (4). Typically, lesions appear on the lower extremities and lymph node, and visceral involvement is uncommon. The disease runs an indolent course and seldom causes death. Spontaneous regression of lesions occurs in approximately 2% of patients (3). Usually it is not associated with immune depression apart from the expected immunologic attrition of aging (5). Endemic KS. Endemic KS occurs in the black population of the rain forest area of Africa, where it makes up 3-9% of cancers (3). In some areas, it is 150-200 times more common than in North America (3). It occurs predominantly in males, but of a younger age group (25-40 years) than in classical KS. They develop nodules of the feet and legs which may regress spontaneously. After an interval of months or years, nodules grow rapidly and ulcerate to give rise to florid tumors or woody infiltration of the limbs (7). Regression is usually achieved with chemotherapeutic agents, and patients live for several years before dying from disseminated disease. This variety of KS is not related to infection with human immunodeficiency virus (HIV). Epidemic KS. Epidemic KS occurs in AIDS patients, in whom the risk of its development is approximately 100 times greater than in the general population (8). More than 24,000 cases have been reported in the United States (9), of which 95% occurred in homosexual/bisexual men and only 5% in other groups at risk for AIDS. KS occurs at an average age of 34 years. The neoplasm is usually widespread and often involves the skin, mucous membranes, gastrointestinal tract, lymph nodes, and almost any organ except the brain (9). Most cases have a rapid fulminant course with extensive skin and visceral involvement (9). Spontaneous remissions occur in less than 4% of cases, usually in those with minimal tumor burdens. KS in organ allograft recipients. An epidemiologic study showed that the incidence of KS in renal transplant patients was increased 400- to 500-fold over that seen in a control population of the same ethnic origin (4). This is borne out by the findings of the Cincinnati Transplant Tumor Registry (CTTR). When nonmelanoma skin cancers and in situ carcinomas of the uterine cervix were excluded, KS comprised 5.7% of neoplasms reported to the CTTR (10). Even more surprising, the total number of cases of KS reported to the CTTR exceeded those of each of two tumors that are common in the general population, namely carcinomas of the colon and breast (10). Clinical Features The average age of presentation of KS in 356 allograft recipients reported to the CTTR was 43 years (range, 4.5-67 years) (11-14). The male-to-female ratio was nearly 3:1, whereas it was as high as 17:1 in classical KS (15). The disease was uncommon in pediatric transplant recipients (16), who comprised only 3% of the patients with KS in the CTTR (11-14), in contrast with endemic KS, which frequently involves children. KS was observed mainly in kidney allograft recipients, with a much smaller incidence in recipients of other solid organs (mainly hearts and livers) (11-14, 17, 18), and was rare in bone marrow allograft recipients (19, 20). The majority of patients (92%) tested negative for HIV (14). The average time of appearance of KS was 21 months (range, 1-225.5 months) after transplantation (11-14). The bulk of the tumors (46%) appeared within 1 year after transplantation. Of 279 patients, whose racial or ethnic origins were noted, the majority were of Arabic, black, Italian, Jewish, or Greek ancestry (11-14). Several studies confirm these findings. KS occurred in 1.6% of 820 Italian renal transplant recipients who were followed for more than 6 months (21). It was the most common cancer in renal transplant recipients in Saudi Arabia, comprising 76% of 46 malignancies in one report (22) and 87.5% of 16 tumors in a different study (23), and affected 4.7% (22) and 5.3% (23), respectively, of renal transplant recipients, whereas in the general population of Saudi Arabia, the incidence of KS was 0.2-0.38%. In Israel, KS occurred in 2.4% of 330 renal allograft recipients (24). In a study of 7923 organ allograft recipients, studied by the research group of the Ile de France, the overall prevalence of KS was 0.52%, but it was significantly higher among liver transplant recipients (1.24%) than among kidney (0.45%) and heart (0.41%) transplant recipients (18). The ethnic origins of the patients were Mediterranean (47%), African (24%), Central European (12%), and other (17%) (18). KS has complicated the use of virtually all widely used immunosuppressive agents, including the more recently introduced compounds tacrolimus and mofetil mycophenolate. A higher proportion of patients who received cyclosporine-based regimens had KS compared with patients who received azathioprine-based regimens (21, 25). It is possible that the differences may merely reflect different racial and ethnic characteristics in the two groups (25). For example, very few transplants were done in Arab countries before cyclosporine was introduced. On the other hand, one study suggests that in kidney allograft recipients, cyclosporine-related KS appeared earlier after transplantation and was a more severe disease, with a higher return to dialysis and death rate, than KS in patients immunosuppressed primarily with azathioprine (18). Patients with KS frequently had other neoplasms. In the CTTR study, 6% of recipients with KS had other malignancies. In the general population, as many as 37% of patients with KS had other primary malignancies, particularly lymphomas (26). In addition, 26% of AIDS patients with non-Hodgkin's lymphoma also had KS (9). The association of the two tumors was also reported in transplant patients (14, 27, 28). In the CTTR, 8 of 356 patients with KS had lymphomas. Sixty percent of patients reported to the CTTR had non-visceral KS confined to the skin, conjunctiva, or oropharyngeal mucosa, and 40% had visceral disease that involved mainly the gastrointestinal tract, lungs, and lymph nodes, but other organs were also affected (14). The majority (98%) of patients with nonvisceral disease had lesions of the skin, and 2% had involvement of the mouth or oropharynx. Diagnosis was difficult in patients who presented without typical skin lesions. Thus, 27% of patients in the CTTR, who had visceral disease, had no skin involvement, but 3% of them did have oral lesions, which provided easy access for biopsy and diagnosis (14). A clinician should suspect KS whenever a transplant patient, particularly one belonging to the ethnic groups described above, presents with reddish blue macules or plaques in the skin or oropharyngeal mucosa, or apparently infected granulomas that fail to heal (11-14). If the diagnosis is confirmed, a thorough workup, including CT scans of the chest and abdomen and upper and lower gastrointestinal endoscopy, is needed to exclude any internal visceral involvement. Diagnostic confusion may occur when KS initially presents as a diffuse pulmonary infiltrate (29). Treatment A variety of treatments have been used for posttransplant KS (4, 11-14, 17-24). Localized nonvisceral disease has resolved after excision, radiation therapy, intralesional injection of chemotherapeutic agents such as bleomycin, reduction of immunosuppressive therapy, administration of α-interferon or cancer chemotherapy, or combinations of the various treatments. Chemotherapeutic agents that have been used successfully include vinblastine, vincristine, etoposide, bleomycin, and mitoxantrone. The role of antiviral agents, such as acyclovir, ganciclovir, and foscarnet, is unclear, but they have been used successfully on occasion, in combination with other treatments. In the CTTR study, 42% of patients with KS had complete remission after various treatments, and 38% of these remissions followed reduction or cessation of immunosuppressive therapy (14). Patients with nonvisceral disease had a higher remission rate (53%) than those with visceral disease (27%). Similar favorable responses to reduction of immunosuppressive therapy were also noted in previous reports (4, 11-14, 17, 18, 28, 30). KS is only one of two neoplasms (the other is non-Hodgkin's lymphoma) in which a substantial percentage of patients show complete or partial remissions after this type of treatment (10-14). However, such therapy does have a price, as 59% of renal recipients, in whom it was successful, lost their allografts and another 6% had impaired function (14). Impressive results were reported in one study in which 8 of 13 patients (61%) had complete remission after reduction of immunosuppressive therapy, and 69% of the patients did not lose their grafts, even many months after reduction or withdrawal of immunosuppression (21). Based on their experience with 26 cases of posttransplant KS, Qunibi et al. (31) believe that gastrointestinal tract involvement does not adversely affect the prognosis. Immunosuppressive management is much more difficult in recipients of nonrenal allografts, such as the liver or heart, as loss of the graft means death unless retransplantation can be performed. For example, of 11 liver transplant recipients in whom immunosuppressive therapy was drastically reduced, 2 had complete remission, 4 had “stabilization” of the lesions, and 5 had progression of KS, of whom 2 developed irreversible chronic rejection and died (17). The importance of the immunosuppressed state in perpetuating the disease is borne out in a multicenter study of eight renal allograft recipients (32). Seven patients with posttransplant KS had been successfully treated by reduction or cessation of immunosuppressive therapy (combined with excision and radiation therapy in one patient) but developed recurrence of KS, either when immunosuppressive therapy was resumed in the regular dosage or when they underwent a second transplant. KS regressed once more when immunosuppression was again reduced or discontinued, but at least four patients lost their allografts to rejection. In the eighth patient, KS had been treated successfully many years before transplantation and developed a recurrence 6 months after transplantation. If KS is not diagnosed or treated soon enough it has a substantial mortality. In the CTTR study, 81 (57%) patients with visceral disease died, of whom 58 (72% of deaths) died of KS per se (14). In contrast, only 49 patients (23%) with nonvisceral KS died, most commonly from infection or rejection or both. It is not clear how many fatal infections were related to overimmunosuppression or to the superimposition of chemotherapy on the existing immunosuppressive regimen. Data are also not available to indicate whether any of the fatal rejections may have been precipitated by reduction or cessation of immunosuppressive therapy. The need for sustained higher immunosuppression in heart and liver transplant recipients probably accounts for the higher mortality in those recipients with KS compared with kidney recipients with KS (18). Posttransplant KS differs from the disease seen in AIDS in that visceral involvement is far less common and fatalities from KS are much less frequent (14). In addition, the immunosuppression in transplant patients can be reduced or totally stopped, with the possibility of subsequent regression of the lesions, whereas in AIDS, persistence of the immunodeficiency is a major feature (14). Pathogenesis One may speculate about possible causes of KS in transplant patients. A theory that may explain the occurrence of KS in transplant and AIDS patients suggests a chronic immunologic reaction between antigenically altered lymphoid cells and normal lymphocytes (33). During the local “graft-versus-host” response, an angiogenesis factor is liberated and causes intense proliferation of mesenchymal and endothelial cells. During this reaction, an oncogenic virus is either transferred to or induced in the cells responsive to the angiogenesis factor and causes their malignant change. As mentioned above, KS is believed to arise from endothelial cells (15, 34). There are structural and functional interactions between vascular and lymphatic endothelium and the immune system (34). Endothelial cells play an important role in lymphocyte traffic and participate in the immune response, acting as antigen-presenting cells (35). It is conceivable that prolonged exposure to the foreign histocompatibility antigens of a transplanted organ or repeated infections by viruses, fungi, bacteria, and protozoa may stimulate macrophages and lymphocytes to liberate cytokines and growth factors that cause endothelial cells to proliferate, thereby leading to the development of KS. That only a small proportion of transplant patients at risk develop KS suggests that an additional factor, such as genetic predisposition or a transmissible agent, contributes to the development of the tumor. In regard to the first possibility, several authors have reported altered frequencies of certain HLA phenotypes in patients with KS (36). These include an increased frequency of A-19, A-23, B-49, B-18, and DR-5, as well as a decreased frequency of B-8 and DR-3. However, none of these studies specifically examined organ transplant recipients. The HLA phenotype and ethnicity of patients reported to the CTTR were examined in 188 patients; HLA-A,B typing was available for 135 patients and HLA-DR typing was available for 67. The most striking characteristic of these patients was their ethnic background: the majority were Arab, Italian, Greek, or Jewish (14, 36). When ethnic background was considered, the expected HLA phenotype frequencies were almost exactly the same as in the KS patients. The quality of donor-recipient HLA match was also examined in 106 patients. Only 22% had four or more mismatches, and 59% had at least two antigens matched. This argues against poor donor-recipient matching as a risk factor for KS developing after transplantation (36). A great deal of evidence has accumulated which suggests that infection with one or more types of virus is at least a cofactor in the etiology of KS (3, 11-15, 33, 34). Many features of KS suggest a viral etiology: its short induction time after the commencing immunosuppressive therapy (11-14); the frequent history of relapses and remissions of individual lesions and the occasional history of apparently spontaneous cures in classical and AIDS-related KS (3); and the regression of KS in some transplant patients when immunosuppressive therapy is reduced or discontinued (11-14). In fact, some investigators regard KS not as a malignancy but as a benign, potentially controllable and reversible hyperplasia (37). Atypical cells and mitotic figures are extremely rare histologic findings, and the multiple lesions, which are so often present, do not fit the conventional understanding of metastases (38). In addition, the occurrence of clusters of the disease in endemic areas of Africa and among AIDS patients favors an infectious etiology. Among viruses that have been linked with KS are hepatitis B virus, Epstein-Barr virus, herpes simplex types 1 and 2, human herpes virus type 6, cytomegalovirus (CMV), papilloma virus type 16, and HIV (11-15, 17, 28, 39). The data in favor of any of these viruses are not convincing (14). For many years CMV was considered the most likely viral agent associated with the development of KS. The presumed relationship was based on seroepidemiologic studies and on detection of CMV DNA in tumor specimens. However, more stringent studies have failed to confirm the connection (14). Recently, a new herpes virus, HHV-8, also known as Kaposi's sarcoma-associated herpes-virus, was isolated from the majority of patients with AIDS-related KS, classical KS, endemic KS, and the KS that occurs in HIV-negative homosexual men and from KS lesions in at least four renal transplant recipients (40-43). The detection of HHV-8 in the various forms of KS argues strongly for an essential role of this virus in the pathogenesis of KS, and makes it unlikely that HHV-8 is only a “passenger” in KS (44). There is a growing body of evidence indicating that HHV-8 is a potent oncogenic virus and the likely infectious cause of KS (45). Its genome has been mapped and its nucleotide sequence has largely been determined (46). The virus encodes homologs to complement-binding proteins, three cytokines (two macrophage inflammatory proteins and interleukin [IL]-6), interferon regulatory factors, IL-8 receptor, and a variety of other proteins. Specific serologic assays show a consistent pattern of high positive test result rates among patients with KS and low positive test result rates among low-risk persons (47). The pattern of viral gene expression suggests that most cells in KS lesions are latently infected, with lytic viral replication likely restricted to a much smaller subpopulation of cells (48). This finding has therapeutic implications, as currently used anti-herpes virus drugs primarily affect lytic virus replication and do not eliminate latent viral infections (47, 48). Based on studies of AIDS-related KS, it is theorized that a transforming virus or agent causes altered phenotypic and functional characteristics of a mesenchymal progenitor cell that predisposes to the development of KS (49). A potential feature of this transformation process is the specific modulation of oncostatin M or IL-6 receptors. The immunosuppressed state and liberation of cytokines such as IL-1, tumor necrosis factor-α, oncostatin M, and IL-6 results in mitogenesis of the progenitor mesenchymal cell. Progression of the process, as well as opportunistic infections, with attendant increases in cytokines (including basic fibroblast growth factor, IL-1β, IL-6, granulocyte-monocyte colony-stimulating factor, platelet-derived growth factor-A and -B, vascular permeability factor, fibroblast growth factor, and tumor necrosis factor-α), results in a rapid increase in the growth rate of KS lesions. Sex steroid hormones may the expression of IL-6 of factors as well as steroid (49). This may for the increased prevalence of KS in The lesions are by proliferation of spindle-shaped considered to be the tumor cells of KS, with and inflammatory with evidence of and The various cytokines may and growth of KS and by may other cells and the lesions The many the who have data their patients to the Cincinnati Transplant Tumor
No takes yet. Share an insight, caveat, or question.
Israel Penn (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: